Table 3

Month	Brimonidine/ Timolol (n=1242)	Dorzolamide/ Timolol (n=2868)	β-blocker+Brimonidine (n=365)	β-blocker+CAI (n=236)	β-blocker+PGA (n=1025)	CAI+Brimoni-dine (n=329)	CAI+PGA (n=618)	PGA+Brimonidine (n=1200)
1	100	100	100	100	100	100	100	100
2	100	100	100	100	100	100	100	100
3	100	100	100	100	100	100	100	100
4	100	100	96.7	90.7^‡	95.7	92.4**	95.8	99.0
5	77.5	95.3^‡	58.4^‡	61.0^‡	61.6^‡	62.3^‡	79.9	70.3*
6	64.1	50.2^‡	45.8^‡	49.2^†	49.9^‡	44.7^‡	54.9**	53.6^†
7	57.6	50.5**	38.9^‡	42.8^‡	44.5^‡	38.0^‡	48.9**	46.3^†
8	54.8	46.8**	36.2^‡	33.9^‡	40.8^‡	35.0^‡	44.5**	43.5^†
9	52.3	42.0^†	31.5^‡	30.1^‡	38.0^‡	29.5^‡	38.5^‡	39.8^‡
10	49.5	36.1^‡	29.9^‡	30.5^‡	36.8^‡	25.5^‡	35.4^‡	38.2^†
11	46.5	30.3^‡	28.8^‡	28.8^‡	34.3^‡	23.4^‡	30.7^‡	35.4^†
12	45.0	24.0^‡	23.0^‡	26.3^‡	31.6^‡	20.1^‡	28.2^‡	33.4^†

CAI: Carbonic Anhydrase Inhibitor; PGA: Prostaglandin Analogue *p<0.05; **p<0.01; ^†p<0.001; ^‡p<0.0001 vs brimonidine/timolol

Table 3: Proportion of patients (%) with glaucoma on fixed-combination brimonidine/timolol versus fixed-combination dorzolamide/timolol or various two-bottle combinations of topical glaucoma therapy (with inclusion of restarts) each month for up to 12 months following the index prescription.